A Form 4 filed with the SEC on September 21, 2026, disclosed that Kevin J. Buchi, a director of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), transferred 20,445 shares of Class A Common Stock to a trust on September 17, 2026, for no consideration.

Key Highlights

  • Reporting person: Kevin J. Buchi, listed as a Director of Amneal Pharmaceuticals, Inc.
  • Transaction: 20,445 shares of Class A Common Stock disposed of via a gift transfer (transaction code G) at a price of $0 on September 17, 2026.
  • Transfer destination: Shares were moved to a trust for which Buchi serves as trustee, according to the filing.
  • Direct holdings after transaction: 75,077 shares of Class A Common Stock held directly following the reported transaction.
  • Indirect holdings: 113,944 shares of Class A Common Stock held indirectly by trust.

Director Buchi's Share Transfer Details at Amneal Pharmaceuticals

According to the Form 4 filing, Kevin J. Buchi, a director at Amneal Pharmaceuticals, Inc., transferred 20,445 shares of Class A Common Stock on September 17, 2026. The filing records the transaction under code "G," which denotes a gift, and states the transfer was made "for no consideration." The filing notes that Buchi is the trustee of the receiving trust.

Following the transaction, the filing reports that Buchi directly holds 75,077 shares of Class A Common Stock. In addition, 113,944 shares are listed as indirectly owned through the trust. The filing was signed by Denis Butkovic as Attorney-in-Fact and dated September 21, 2026. No derivative securities transactions were reported in this filing.

What Was Disclosed

The filing discloses a gift transfer of 20,445 shares of Class A Common Stock by director Kevin J. Buchi to a trust for no consideration on September 17, 2026, with Buchi retaining indirect beneficial ownership as trustee of that trust.